Psyence Biomedical Common SharesNASDAQ: PBM

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Psyence Biomedical Common Shares is in the Healthcare sector

Psyence Biomedical Common Shares is in the Biotechnology industry

Psyence Biomedical Common Shares is headquartered in Canada

Psyence Biomedical Common Shares initial public offering (IPO) was on 10 December 2021

https://www.psyencebiomed.com

No, Psyence Biomedical Common Shares is not included in the S&P 500 index

No, Psyence Biomedical Common Shares is not included in the NASDAQ 100 index

No, Psyence Biomedical Common Shares is not included in the Dow Jones index

No data